Vasopressin in chronic kidney disease: An elephant in the room

Research output: Contribution to journalComment/debate

36 Scopus citations

Abstract

Perico et al. report that a dual arginine vasopressin (AVP) V 2 and V 1a receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V 2 and V 1a receptors and potential usefulness of V 2 and V 1a receptor antagonists remain ill defined.

Original languageEnglish (US)
Pages (from-to)925-928
Number of pages4
JournalKidney international
Volume76
Issue number9
DOIs
StatePublished - Nov 2009

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Vasopressin in chronic kidney disease: An elephant in the room'. Together they form a unique fingerprint.

  • Cite this